News headlines about Achaogen (NASDAQ:AKAO) have trended somewhat positive on Sunday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Achaogen earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.9329472954419 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.78 Million (americanbankingnews.com)
- Achaogen, Inc. (AKAO) Expected to Post Earnings of -$0.79 Per Share (americanbankingnews.com)
- Achaogen (AKAO) Earns Buy Rating from Mizuho (americanbankingnews.com)
- Achaogen to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference – GlobeNewswire (press release) (globenewswire.com)
- Microbot Medical Inc., (NASDAQ: MBOT), Ceragon Networks Ltd., (NASDAQ: CRNT), Achaogen, Inc., (NASDAQ: AKAO … – Stocks In The News (press release) (tradingnewsnow.com)
AKAO has been the topic of several analyst reports. Leerink Swann reissued an “outperform” rating and set a $22.00 target price (down previously from $28.00) on shares of Achaogen in a research report on Monday, October 9th. They noted that the move was a valuation call. Mizuho started coverage on Achaogen in a research report on Wednesday, September 6th. They set a “buy” rating and a $28.00 target price on the stock. Guggenheim started coverage on Achaogen in a research report on Tuesday, October 24th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Achaogen in a research report on Thursday, November 9th. Finally, Stifel Nicolaus cut their price objective on Achaogen from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company. Achaogen currently has a consensus rating of “Buy” and an average target price of $25.78.
Achaogen (NASDAQ:AKAO) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.13). The business had revenue of $0.58 million during the quarter, compared to the consensus estimate of $2.09 million. Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The business’s revenue was down 96.4% compared to the same quarter last year. During the same period last year, the company earned ($0.41) EPS. equities analysts expect that Achaogen will post -3.06 EPS for the current fiscal year.
In other Achaogen news, COO Blake Wise sold 3,576 shares of the company’s stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $15.99, for a total value of $57,180.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 8.36% of the company’s stock.
WARNING: “Achaogen (AKAO) Given Daily News Sentiment Rating of 0.10” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/03/achaogen-akao-given-daily-news-sentiment-rating-of-0-10.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
What are top analysts saying about Achaogen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Achaogen Inc. and related companies.